BTN2A1

Across TCGA pan-cancer cohorts, BTN2A1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of BTN2A1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where BTN2A1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types BTN2A1 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD, CCRCC, and LSCC are the cancer types where BTN2A1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BTN2A1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	−0.691	<.001	9	view →
CCRCC	All	II,III,IV	+0.334	<.001	9	view →
LSCC	Male	II,III,IV	−0.680	<.001	8	view →
HNSC	Male	II,III,IV	−0.369	.027	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

BTN2A1–LUAD

Open the LUAD breakdown →